Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Brian Wilder

Internal Medicine Jennings, LA Medical Doctor

NPI 1558455733 CMS profile 206054

2539 F E Landry Rd, Jennings, LA 70546

Open in the dashboard

General payments

$3,664

228 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brian Wilder of Jennings, LA is reported in the CMS Open Payments database as having received $3,664 across 228 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 86th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $339 21
2024 General $422 25
2023 General $325 20
2022 General $818 50
2021 General $962 56
2020 General $456 33
2019 General $341 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brian Wilder
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Brian Wilder were reported at $339. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Brian Wilder Internal Medicine median Middle half National median
2019 $341 $159 $48–$570 $163
2020 $456 $119 $33–$402 $114
2021 $962 $135 $37–$521 $132
2022 $818 $141 $42–$496 $149
2023 $325 $149 $45–$519 $160
2024 $422 $154 $47–$537 $164
2025 $339 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $745 53 payments
  2. Esperion Therapeutics, Inc. $348 22 payments
  3. Astellas Pharma US Inc $347 18 payments
  4. AbbVie, Inc. $339 23 payments
  5. Lilly USA, LLC $324 18 payments
  6. AstraZeneca Pharmaceuticals LP $219 13 payments
  7. Sanofi-Aventis U.S. LLC $192 14 payments
  8. Takeda Pharmaceuticals U.S.A., Inc. $170 13 payments
  9. Boehringer Ingelheim Pharmaceuticals, Inc. $141 2 payments
  10. Novartis Pharmaceuticals Corporation $135 9 payments
  11. Other $702 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,564 227 payments
  2. Education $100 1 payment
Products named General payments · program years 2019–2025
  1. RYBELSUS $572 41 payments
  2. Ozempic $516 43 payments
  3. NEXLETOL $348 22 payments
  4. JARDIANCE Diabetes $171 8 payments
  5. MYRBETRIQ $162 12 payments
  6. JARDIANCE Diabetes $141 2 payments
  7. MOUNJARO $138 9 payments
  8. QULIPTA $138 7 payments
  9. UBRELVY $130 9 payments
  10. FARXIGA $124 7 payments
  11. Other $2,082 139 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 253 drugs

Part D claims

27,015

Median for Internal Medicine: 777

Drug cost

$1,762,436

Median for Internal Medicine: $73,373

Branded share of claims

24.2%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 250 $284,647
Eliquis Apixaban Brand 339 $145,773
Mounjaro Tirzepatide Brand 122 $135,255
Januvia Sitagliptin Phosphate Brand 248 $86,165
Farxiga Dapagliflozin Propanediol Brand 131 $74,204
Xarelto Rivaroxaban Brand 134 $71,926
Rexulti Brexpiprazole Brand 87 $63,413
Teriflunomide Generic 12 $56,562
Linzess Linaclotide Brand 96 $54,164
Trulicity Dulaglutide Brand 49 $46,900

The 10 drugs with the highest cost, of 253 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 111 billing codes

Paid by Medicare

$431,386

Of which drugs: $25,717

Medicare patients

920

Average age 76

Services billed

11,825

531 women, 389 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Depression 51%
Ischemic heart disease 45%
Diabetes 44%
Chronic kidney disease 40%
Heart failure 32%
Atrial fibrillation 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 236 236 $19,228
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 170 664 $3,297
Vaccine for pneumococcal polysaccharide for injection beneath the skin or into muscle, patient 2 years or older 90732 Office 22 22 $2,878
Injection, ceftriaxone sodium, per 250 mg J0696 Office 100 289 $91
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg J3420 Office 22 46 $36

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 12 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $85
$85 — —
NEXLETOL
  • Esperion Therapeutics, Inc. $55
$55 — —
Wegovy
  • Novo Nordisk Inc $43
$43 — —
JATENZO
  • TOLMAR, INC. $35
$35 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $23
$23 80 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 12 in the dashboard with a free account

Records

228 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record